339 related articles for article (PubMed ID: 27459603)
1. Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients.
Shekhar S; Kumar R; Rai N; Kumar V; Singh K; Upadhyay AD; Tripathi M; Dwivedi S; Dey AB; Dey S
PLoS One; 2016; 11(7):e0159099. PubMed ID: 27459603
[TBL] [Abstract][Full Text] [Related]
2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
3. Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.
Yang CC; Chiu MJ; Chen TF; Chang HL; Liu BH; Yang SY
J Alzheimers Dis; 2018; 61(4):1323-1332. PubMed ID: 29376870
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
Tieu MV; Choi SH; Le HTN; Cho S
Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
[TBL] [Abstract][Full Text] [Related]
6. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
[TBL] [Abstract][Full Text] [Related]
7. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Janelidze S; Mattsson N; Palmqvist S; Smith R; Beach TG; Serrano GE; Chai X; Proctor NK; Eichenlaub U; Zetterberg H; Blennow K; Reiman EM; Stomrud E; Dage JL; Hansson O
Nat Med; 2020 Mar; 26(3):379-386. PubMed ID: 32123385
[TBL] [Abstract][Full Text] [Related]
8. Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
Nam E; Lee YB; Moon C; Chang KA
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679907
[TBL] [Abstract][Full Text] [Related]
9. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Li Z; Fan Z; Zhang Q
J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
[TBL] [Abstract][Full Text] [Related]
10. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.
Spiegel J; Pirraglia E; Osorio RS; Glodzik L; Li Y; Tsui W; Saint Louis LA; Randall C; Butler T; Xu J; Zinkowski RP; Zetterberg H; Fortea J; Fossati S; Wisniewski T; Davies P; Blennow K; de Leon MJ
J Alzheimers Dis; 2016; 49(1):93-100. PubMed ID: 26444757
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
12. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
13. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
14. Platelet Amyloid-β Protein Precursor (AβPP) Ratio and Phosphorylated Tau as Promising Indicators for Early Alzheimer's Disease.
Shi Y; Gu L; Wang Q; Gao L; Zhu J; Lu X; Zhou F; Zhu D; Zhang H; Xie C; Zhang Z
J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):664-670. PubMed ID: 31336382
[TBL] [Abstract][Full Text] [Related]
15. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
16. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
17. Serum FOXO3A: A ray of hope for early diagnosis of Alzheimer's disease.
Pradhan R; Yadav SK; Prem NN; Bhagel V; Pathak M; Shekhar S; Gaikwad S; Dwivedi SN; Bal CS; Dey AB; Dey S
Mech Ageing Dev; 2020 Sep; 190():111290. PubMed ID: 32603667
[TBL] [Abstract][Full Text] [Related]
18. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
[TBL] [Abstract][Full Text] [Related]
19. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
20. CSF Aβ
Rizzi L; Maria Portal M; Batista CEA; Missiaggia L; Roriz-Cruz M
Brain Res; 2018 Jan; 1678():27-31. PubMed ID: 29017912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
